Should I start with a 5 mg or 10 mg daily dose for a urine albumin‑to‑creatinine ratio of 328 mg/g?

Start with 10 mg daily for a urine albumin-to-creatinine ratio of 328 mg/g

For a patient with a UACR of 328 mg/g (which falls in the A3 category of severely increased albuminuria), you should initiate finerenone at 10 mg once daily if the eGFR is between 25-60 mL/min/1.73 m², or 20 mg once daily if the eGFR is ≥60 mL/min/1.73 m². 1

Understanding the Clinical Context

Your patient has severely increased albuminuria (A3 category) based on the UACR of 328 mg/g, which exceeds the 300 mg/g threshold 2. This level of albuminuria indicates:

• High risk for cardiovascular events and mortality
• High risk for CKD progression
• Likely presence of diabetic kidney disease if diabetes is present
• Need for aggressive intervention with kidney-protective medications

Dosing Algorithm for Finerenone

The starting dose depends entirely on the patient's baseline eGFR 1:

If eGFR is 25-60 mL/min/1.73 m²:

• Start with 10 mg once daily
• After 1 month, increase to 20 mg once daily if:
  • Serum potassium remains ≤4.8 mmol/L
  • eGFR is stable

If eGFR is ≥60 mL/min/1.73 m²:

• Start with 20 mg once daily
• Continue monitoring potassium and kidney function

Critical Safety Considerations

Potassium monitoring is essential - the serum potassium must be ≤4.8 mmol/L before initiating therapy 1. Hyperkalemia is the primary safety concern, causing discontinuation in 2.3% of patients in the FIDELIO-DKD trial (compared to 0.9% with placebo), though no deaths occurred from hyperkalemia 1.

Evidence Supporting This Approach

The FIDELIO-DKD trial demonstrated that finerenone significantly reduced:

• The composite kidney outcome (HR 0.82, P = 0.001)
• Cardiovascular outcomes (HR 0.86, P = 0.03)

The trial specifically enrolled patients with UACR of 300-5,000 mg/g and eGFR 25-75 mL/min/1.73 m², making your patient with UACR 328 mg/g directly comparable to the study population 1.

Additional Management Priorities

Beyond finerenone dosing, patients with this level of albuminuria require:

• ACE inhibitor or ARB therapy (if not already on maximum tolerated doses) 3
• SGLT2 inhibitor for additional kidney and cardiovascular protection
• Blood pressure target <130/80 mmHg 4
• Monitoring for treatment response: A reduction in UACR of ≥30% from baseline indicates effective therapy and reduced risk for cardiovascular and kidney events 5

Common Pitfalls to Avoid

1. Don't delay treatment - This level of albuminuria requires immediate intervention to prevent progression to end-stage kidney disease
2. Don't forget potassium monitoring - Check potassium before starting and regularly during dose titration
3. Don't use finerenone as monotherapy - It should complement, not replace, ACE inhibitors/ARBs and SGLT2 inhibitors
4. Don't ignore the eGFR - The starting dose is eGFR-dependent, not albuminuria-dependent